Hereditary angioedema: Safety of long-term stanozolol therapy
- PMID: 17765757
- DOI: 10.1016/j.jaci.2007.06.037
Hereditary angioedema: Safety of long-term stanozolol therapy
Abstract
Background: Attenuated androgens control attacks of hereditary angioedema. Short-term studies of such patients treated at our institution with attenuated androgens demonstrated no adverse effects. However, the side-effect frequencies in patients receiving long-term treatment are relatively less well characterized.
Objective: To assess the frequencies of various side effects of the attenuated androgen stanozolol in a population of patients with hereditary angioedema treated for 20 to 40 years.
Methods: Data on side effects in patients who continued stanozolol therapy since 1987 were obtained by means of questionnaire. Patients were evaluated by physical examination; biochemical assays of hepatic function, serum lipids, and prostate specific antigen; and liver ultrasound.
Results: The minimal initial effective dosage of stanozolol was 0.5 to 2.0 mg daily, although most patients achieved symptomatic control and decreased the dose and frequency as the frequency of attacks decreased. Treatment-related symptoms developed in 10 of 21 patients. No interruption in stanozolol therapy was required because symptoms subsided with a reduction in the stanozolol dosage. Adverse side effects included hirsutism, weight gain, menstrual irregularities or postmenopausal bleeding, acne, and mood changes. Liver enzyme assays revealed no persistent abnormalities. Liver ultrasounds in 8 patients revealed 3 abnormalities deemed unrelated to therapy. Five patients had a reduced high-density lipoprotein, and 2 patients had elevated triglycerides.
Conclusion: Stanozolol is a safe and effective drug for the long-term management of hereditary angioedema.
Clinical implications: Stanozolol may be used in the long-term treatment of patients with hereditary angioedema provided such patients are closely supervised with routine clinical, biochemical, and radiologic assessments.
Similar articles
-
Hereditary angioedema: a decade of management with stanozolol.J Allergy Clin Immunol. 1987 Dec;80(6):855-60. doi: 10.1016/s0091-6749(87)80277-4. J Allergy Clin Immunol. 1987. PMID: 3693762
-
Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients.Ann Allergy Asthma Immunol. 2008 Feb;100(2):153-61. doi: 10.1016/S1081-1206(10)60424-3. Ann Allergy Asthma Immunol. 2008. PMID: 18320917
-
[Hereditary angioedema. A clinical and immunologic contribution based on our 8 clinical cases under long-term treatment with androgens].Schweiz Med Wochenschr. 1983 Jun 18;113(24):876-84. Schweiz Med Wochenschr. 1983. PMID: 6879139 German.
-
[Profhylaxis and treatment of hereditary and acquired angioedema at HUB; use of the C1-esterase inhibitor].Farm Hosp. 2003 Nov-Dec;27(6):346-52. Farm Hosp. 2003. PMID: 14974880 Review. Spanish.
-
Hereditary angioedema: clinical and biochemical heterogeneity.Ann Allergy. 1988 Aug;61(2):69-74. Ann Allergy. 1988. PMID: 3041877 Review.
Cited by
-
The effect of long-term danazol prophylaxis on liver function in hereditary angioedema-a longitudinal study.Eur J Clin Pharmacol. 2010 Apr;66(4):419-26. doi: 10.1007/s00228-009-0771-z. Epub 2009 Dec 19. Eur J Clin Pharmacol. 2010. PMID: 20024535
-
Angioedema of Vermilion Border Lip: A Case Report.Cureus. 2022 Oct 10;14(10):e30142. doi: 10.7759/cureus.30142. eCollection 2022 Oct. Cureus. 2022. PMID: 36381703 Free PMC article.
-
Ecallantide for the treatment of hereditary angiodema in adults.Clin Med Insights Cardiol. 2011;5:49-54. doi: 10.4137/CMC.S4434. Epub 2011 May 17. Clin Med Insights Cardiol. 2011. PMID: 21695090 Free PMC article.
-
Medicinal Use of Testosterone and Related Steroids Revisited.Molecules. 2021 Feb 15;26(4):1032. doi: 10.3390/molecules26041032. Molecules. 2021. PMID: 33672087 Free PMC article. Review.
-
Hereditary angioedema in women.Allergy Asthma Clin Immunol. 2010 Jul 28;6(1):17. doi: 10.1186/1710-1492-6-17. Allergy Asthma Clin Immunol. 2010. PMID: 20667120 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources